Cisplatin in Dogs
Generic: Cisplatin
Cisplatin is a potent platinum-based chemotherapy agent used primarily in veterinary oncology to treat specific solid tumors in dogs.
This medication is intended for dogs.
Overview
Cisplatin is an inorganic platinum complex that serves as a cornerstone in the treatment of various solid malignancies in veterinary medicine. It belongs to a class of alkylating-like agents that interfere with DNA replication, thereby arresting the growth of rapidly dividing malignant cells. While highly effective, it requires strict clinical oversight due to its significant potential for toxicity, particularly regarding renal health, which often necessitates aggressive fluid therapy protocols during administration. It is frequently employed alongside other chemotherapeutic agents such as Cyclophosphamide or Vinblastine to create multi-modal therapeutic regimens tailored to the specific tumor histology.
In canine oncology, this medication is most notably recognized for its efficacy against osteosarcoma and certain carcinomas, providing a palliative or adjuvant option where other therapies may be insufficient. Because its toxic profile is markedly severe in feline patients—often resulting in fatal pulmonary edema—it is strictly contraindicated for use in cats. When utilized in dogs, clinicians must carefully evaluate renal function, liver enzymes, and overall performance status before initiating treatment. The therapeutic approach often involves alternating or combining cisplatin with drugs like Mitoxantrone or Lomustine (CCNU) to optimize outcomes while managing the cumulative toxicity limits that define the drug's usage.
Beyond its core tumor-fighting capabilities, cisplatin is often sequenced in complex protocols that might involve agents like Vincristine to target different phases of the cell cycle. The management of a patient receiving cisplatin requires a multidisciplinary approach, often involving board-certified veterinary oncologists who can mitigate side effects through preemptive antiemetic therapy and rigorous electrolyte monitoring. Understanding the pharmacokinetic limitations, such as the total cumulative dose allowed over the lifespan of the dog, is essential to preventing permanent organ damage. Clinicians balance the benefit of tumor regression against the inherent risks associated with this heavy-metal chemotherapy.
What It Treats
- Osteosarcoma: Used as an adjuvant therapy in dogs to reduce metastatic spread after primary tumor resection.
- Transmissible Venereal Tumor (TVT): Often utilized in cases that are resistant to other standard chemotherapy protocols.
- Squamous Cell Carcinoma: Effective in treating certain epithelial-based tumors in specific anatomical locations.
- Carcinomas: Used in the management of localized or metastatic solid carcinomas that have shown resistance to primary treatments.
How It Works
Cisplatin functions by entering the tumor cell and undergoing aquation to form highly reactive platinum complexes. These complexes bind covalently to DNA, primarily at the N7 position of guanine, creating intra-strand and inter-strand cross-links. This chemical bonding severely distorts the DNA helix, preventing normal unwinding and transcription, which triggers cellular apoptosis (programmed cell death) as the cell fails to replicate its genetic material accurately. Because cisplatin targets DNA synthesis, its mechanism is non-cell-cycle specific, though it is most destructive during the S-phase of cell division. By inhibiting the cell's ability to repair or replicate its genetic code, the medication effectively shuts down the proliferative capacity of malignant tissue. The reliance on this mechanism also explains the drug's impact on healthy, rapidly dividing cells, such as those in the bone marrow and gastrointestinal lining, which contributes to the side effects observed in treated patients.
Dosage
Dosage is strictly calculated based on the dog's body surface area (mg/m2) rather than body weight, as this provides a more accurate reflection of metabolic demand and drug tolerance. Due to the high risk of renal toxicity, veterinarians must follow rigid protocols involving pre- and post-administration intravenous diuresis. Owners should never adjust or miss doses, as this can severely compromise the chemotherapy plan and safety.
Administration
Cisplatin is administered exclusively via slow intravenous infusion in a clinical setting by trained veterinary staff. The procedure typically requires several hours to allow for adequate pre-hydration with intravenous fluids, which is critical to dilute the drug and protect the kidneys. Because the medication is a cytotoxic vesicant, meticulous care is taken to ensure the venous access is secure to prevent extravasation, which could lead to severe tissue necrosis at the injection site.
Storage
The medication must be stored in its original, light-resistant container at controlled room temperature, away from extreme heat, moisture, and direct sunlight. Once reconstituted or diluted for administration, it should be used immediately, as it does not contain preservatives. Because it is a hazardous cytotoxic agent, it should be kept in a secured, restricted-access storage area within the veterinary clinic.
Contraindications
Cisplatin is absolutely contraindicated for use in cats, as it causes severe and fatal pulmonary edema, a reaction that is unique to the feline species. It should also be avoided in dogs with pre-existing renal insufficiency, significant dehydration, or bone marrow suppression, as the drug's metabolic pathway and toxic profile exacerbate these conditions. Furthermore, caution is required in patients with compromised hepatic function or those currently experiencing active infections. Before administration, a thorough clinical evaluation, including a complete blood count (CBC) and serum biochemistry profile, must confirm that the patient is physically robust enough to handle the chemotherapy-induced stress on organ systems.
Interactions
Concurrent use of nephrotoxic drugs, such as certain aminoglycoside antibiotics or non-steroidal anti-inflammatory drugs like [Firocoxib](/medications/firocoxib-oncology-in-dogs), must be avoided or managed with extreme caution due to the cumulative risk of kidney damage. The concomitant use of diuretics may be necessary for safety, but their selection must be supervised by an oncologist to prevent dehydration. Additionally, administering cisplatin alongside other myelosuppressive chemotherapy agents necessitates careful spacing to prevent life-threatening depletion of white blood cells and platelets. There are no specific food interactions, but the patient's nutritional status should be monitored closely, as chemotherapy can influence appetite and overall metabolic efficiency.
Side Effects
- Nephrotoxicity (kidney damage)
- Severe vomiting and nausea
- Myelosuppression (low blood cell counts)
- Ototoxicity (hearing loss)
- Peripheral neuropathy
- Anaphylactic-like allergic reactions
- Electrolyte imbalances
Sources & References
Frequently Asked Questions
This information is educational only and not a substitute for professional veterinary advice. Always consult a licensed veterinarian before starting or changing any medication.
